
ADA: Oral Insulin May Delay Type 1 Diabetes Onset
Home / Conditions / Type 1 Diabetes / ADA: Oral Insulin May Delay Type 1 Diabetes Onset
ADA: Oral Insulin May Delay Type 1 Diabetes Onset
In adults with two or more antibodies predicting the development of type 1 diabetes, treatment with daily oral insulin therapy did not prevent development of the disease, but a small subset experienced a 31-month delay in clinical diabetes development.
Close relatives of people with type 1 diabetes who had certain autoantibodies that put them at high risk of progression to clinical type 1 diabetes did not benefit from taking oral insulin vs placebo, according to a new trial. The participants were mostly children and adolescents, with a median age of 8. However, surprisingly, among a small subset of participants with the same autoantibodies against islet cells but with low insulin secretion, those who received insulin tablets were diagnosed with type 1 diabetes 2.5 years later than those who got placebo.
This was the largest trial ever performed using oral insulin and even though the results were not a homerun, a pre-specified secondary hypothesis was met and there were no significant adverse events. The results showed an incremental advance as it was able to delay type 1 diabetes for 2.5 years in a subset.
Dr. Carla J. Greenbaum, who presented the results, stated that people with close relatives with type 1 diabetes have a 15-fold increased risk of developing the disease themselves.
An earlier study had suggested that if such individuals also had high levels of micro insulin autoantibodies (mIAA), taking oral insulin might buy tim
Continue
reading